JP Morgan Chase’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
EIG
JP Morgan Chase's DGX Position: Q2 2026 in Review
JP Morgan Chase reduced its Quest Diagnostics (DGX) stake by 8.5% in Q2 2026, selling an estimated $64M and leaving 3,520,438 shares worth $749M. The position accounts for 0.04% of the portfolio, ranked #346.
JP Morgan Chase first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. The position peaked at $823M in Q3 2025. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- JP Morgan Chase held 3,520,438 shares of Quest Diagnostics worth $749M as of Q2 2026.
- JP Morgan Chase sold 326,018 Quest Diagnostics shares in Q2 2026, an estimated $64M.
- Quest Diagnostics made up 0.04% of JP Morgan Chase's portfolio in Q2 2026, its #346 holding.
- JP Morgan Chase first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
- JP Morgan Chase's Quest Diagnostics position peaked at $823M in Q3 2025.
- 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.